2016 News

• 12.16.2016
  Press Release IR News

  Notice of Change in Significant Shareholder

• 12.14.2016
  Press Release IR News

  Notice of Cancellation of Treasury Shares

• 11.28.2016
  Press Release IR News

  Santen Announces Phase III SAKURA Program Topline Results in Patients with Non-Infectious Uveitis of the Posterior Segment

• 11.24.2016
  Press Release IR News

  Santen Announces Completion of Share Repurchase Program

• 11.02.2016
  Press Release IR News

  Santen Reports the 2nd Quarter Fiscal 2016 Consolidated Performance

• 11.01.2016
  Press Release IR News

  Santen Announces Status of Repurchase of Own Shares

• 10.06.2016
  Press Release IR News

  Santen, RIKEN and FBRI Announce Research Collaboration to Develop New Retinal Disease Treatments

• 10.03.2016
  Press Release IR News

  Personnel Changes of Corporate Officer

• 10.03.2016
  Press Release IR News

  Santen Announces Status of Repurchase of Own Shares

• 09.12.2016
  Press Release IR News

  Santen Announces Repurchase of Own Shares

• 09.01.2016
  Press Release IR News

  Notice on Details of Subscription Rights to New Shares (Stock Options for Stock-Linked Remuneration)

• 08.30.2016
  Press Release IR News

  Santen Announces the Completion of Establishment Procedures for Chongqing Santen Kerui Pharmaceutical Co., Ltd.

• 08.22.2016
  Press Release IR News

  Santen Completes Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device

• 08.03.2016
  Press Release IR News

  Santen and University College London to collaborate on ophthalmic research and education

• 08.02.2016
  Press Release IR News

  Santen Reports the 1st Quarter Fiscal 2016 Consolidated Performance

• 08.02.2016
  Press Release IR News

  Santen to Grant Subscription Rights to New Shares as Stock Options for Stock-Linked Remuneration

• 07.19.2016
  Press Release IR News

  Santen to Acquire InnFocus, Developer of MicroShunt Glaucoma Implant Device

• 07.04.2016
  Press Release IR News

  Santen Receives Positive Recommendation from CDSCO for Sirolimus

• 05.31.2016
  Information

  CONVOCATION NOTICE OF THE 104TH ANNUAL GENERAL MEETING OF SHAREHOLDERS

• 05.12.2016
  Press Release IR News

  Vekacia® (Ciclosporin 1mg/mL Eye Drops) Pivotal Trial Meets Primary and Key Secondary Endpoints

• 05.11.2016
  Press Release IR News

  Flash Report on FY2015 Financial Results

• 05.11.2016
  Press Release IR News

  Santen Provides Update on EU Marketing Authorization Application for DE-109 (Sirolimus)

• 05.11.2016
  Press Release IR News

  Notice of Board of Directors and Corporate Auditor Nominations

• 04.18.2016
  Press Release

  Santen Donates to Kumamoto Earthquake Relief Efforts

• 03.30.2016
  Press Release IR News

  Santen Enters Licensing Agreement with Ono for FP/EP3 Dual Agonist, ONO-9054

• 03.22.2016
  Press Release IR News

  Santen China and Chongqing Kerui Announce Collaboration to Develop New Ophthalmic Joint Venture

• 03.10.2016
  Press Release IR News

  Notice of Corporate Officer Appointments

• 02.23.2016
  Press Release IR News

  Santen Announces Proposed Dividend Change

• 02.10.2016
  Press Release IR News

  Notice on the Establishment of Santen Business Services Co., Ltd.

• 02.09.2016
  Press Release

  Santen Makes Contribution to Support the Recovery of Areas Affected by the Earthquake in Taiwan

• 02.02.2016
  Press Release IR News

  Santen Announces Financial Result for the Third Quarter ended December 31, 2015

• 01.18.2016
  IR News

  "Specialized in Ophthalmology" Santen Presents at J.P. Morgan Conference

News Archive